Perspective Therapeutics Inc CATX

Healthcare Biotechnology

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

NYSEAM:CATX - Post by User

Perspective Therapeutics Inc

Bullboard Posts

Post by kingposton May 28, 2015 2:59pm

306 Views

Post# 23775097

April enquiries double past 2 yrs --from Maxim

"If Maxim is correct with their statement that April 2015 had more inquiries from clinics that the prior 2 years combined. Then sales could show up in the next earnings and then we have another catalyst. We may be witness to Babs proverbial "Hockey Stick"."

Bullboard Posts

@ the Bell: TSX advances to start off Christmas trading week